BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 37286711)

  • 1. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.
    Gao F; Yuan Y; Ding Y; Li PY; Chang Y; He XX
    Curr Med Sci; 2023 Jun; 43(3):526-538. PubMed ID: 37286711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
    Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
    Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DLAT is a promising prognostic marker and therapeutic target for hepatocellular carcinoma: a comprehensive study based on public databases.
    Zhang P; Zhao JH; Yuan LX; Ju LL; Wang HX; Wang F; Chen L; Cai WH
    Sci Rep; 2023 Oct; 13(1):17295. PubMed ID: 37828099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis regulatory genes greatly contribute to clinical assessments of hepatocellular carcinoma.
    Ke C; Dai S; Xu F; Yuan J; Fan S; Chen Y; Yang L; Li Y
    BMC Cancer; 2023 Jan; 23(1):25. PubMed ID: 36611155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cuproptosis-related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features.
    Li S; Weng J; Xiao C; Lu J; Cao W; Song F; He Z; Zhang P; Zhu Z; Xu J
    Cancer Rep (Hoboken); 2023 Dec; 6(12):e1904. PubMed ID: 37885090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cuproptosis-related molecular classification and gene signature of hepatocellular carcinoma and experimental verification.
    Chen Z; Du D; Li J; Zhang W; Shao J
    Transl Cancer Res; 2024 Mar; 13(3):1268-1289. PubMed ID: 38617510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
    Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
    Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
    Chen X; Hu G; Xiong L; Xu Q
    Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
    Li Y; Zeng X
    Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
    [No Abstract]   [Full Text] [Related]  

  • 12. MELK promotes HCC carcinogenesis through modulating cuproptosis-related gene DLAT-mediated mitochondrial function.
    Li Z; Zhou H; Zhai X; Gao L; Yang M; An B; Xia T; Du G; Li X; Wang W; Jin B
    Cell Death Dis; 2023 Nov; 14(11):733. PubMed ID: 37949877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Cuproptosis-Related Signature Identified DLAT as a Prognostic Biomarker for Hepatocellular Carcinoma Patients.
    Bai WD; Liu JY; Li M; Yang X; Wang YL; Wang GJ; Li SC
    World J Oncol; 2022 Oct; 13(5):299-310. PubMed ID: 36406193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma.
    Zhu J; Wang J; Liu H; Lei T; Yang J; Lan S; Jian H; Fang H; Zhang Y; Ren K; Zhong F
    Aging (Albany NY); 2023 Dec; 15(23):13901-13919. PubMed ID: 38078880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
    Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
    BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma.
    Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Front Genet; 2023; 14():1056000. PubMed ID: 36845390
    [No Abstract]   [Full Text] [Related]  

  • 17. Comprehensive analysis identifies cuproptosis-related gene DLAT as a potential prognostic and immunological biomarker in pancreatic adenocarcinoma.
    Zhang X; Zhou Y; Hu J; Yu X; Xu H; Ba Z; Zhang H; Sun Y; Wang R; Du X; Mou R; Li X; Zhu J; Xie R
    BMC Cancer; 2023 Jun; 23(1):560. PubMed ID: 37330494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma.
    Li D; Jin S; Chen P; Zhang Y; Li Y; Zhong C; Fan X; Lin H
    Front Immunol; 2022; 13():991604. PubMed ID: 36685508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma.
    Jiang H; Chen H; Wang Y; Qian Y
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
    Liu R; Liu Y; Zhang F; Wei J; Wu L
    Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.